Fig. 2: Role of alternative polyadenylation in shaping the molecular and clinical features of lung cancer.

a Global shortening of 3′UTR detected by DexSeq2 analysis. The dot plot map shows genes undergoing significant 3′UTR shortening (red) or significant 3′UTR lengthening (blue) and no changes (gray) in tumors compared with adjacent non-involved tissues. Each dot corresponds to a gene. b Genomic location of regulated proximal and distal sites in tumors. c Breakdown of regulated sites by sense/anti-sense strands. d Expression of polyadenylation-related genes in tumor and adjacent non-involved tissues. Heatmap of combined z-score and gene expression analysis of 29 known polyadenylation factors in tumors compared to non-involved tissues. The asterisk indicates the degree of significance of differentially expressed genes. e Enriched pathways. Pathway significantly enriched have a −log10 (p-value) greater than 1.3 (p-value < 0.05; Fisher’s exact test; one-tailed test). Ingenuity canonical pathways analysis in genes with enhanced proximal and distal sites. f Relationship between 3′UTR shortening and lung cancer survival. A two-sided log-rank test is used to compare the survival times between two groups. The p‐value of the log‐rank test statistic is commonly approximated by the chi‐square distribution and thus only approximate in a higher limit. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.